Catalog No.: PC-36090Not For Human Use, Lab Use Only.
Crisdesalazine (AAD-2004, AAD2004) is a derivative of aspirin that inhibits microsomal PGE(2) synthase-1 (mPGES-1) activity in response to both LPS-treated BV2 cell with IC50 of 230 nM and recombinant human mPGES-1 protein with IC50 of 249 nM in vitro.
Crisdesalazine (AAD-2004, AAD2004) is a derivative of aspirin that inhibits microsomal PGE(2) synthase-1 (mPGES-1) activity in response to both LPS-treated BV2 cell with IC50 of 230 nM and recombinant human mPGES-1 protein with IC50 of 249 nM in vitro.
Crisdesalazin blocked free radical production, PGE(2) formation, and microglial activation in the spinal cords in superoxide dismutase 1(G93A) transgenic mouse model of ALS.
Crisdesalazin reduced autophagosome formation, axonopathy, and motor neuron degeneration, improving motor function and increasing life span, which is superior to riluzole or ibuprofen.
